Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

4    Novartis    $19.2B    up 6.7%


Global revenue:  $58.5B (3rd); up 15.6%

R&D spend: $9.2B (1st), up 13.6%; 15.7% of rev.

Top brands: Diovan/Co-Diovan ($2.3B); Gleevec ($1.5B); Zometa ($642M); Sandostatin ($574M)

Planned launches: Bexsero (men. B vacc.); Seebri Breezhaler (NVA237)/QVA149 (COPD)

Promotional spend: $973M (6th); 5.1% of rev.

Patent expirations: Diovan (2012); Zometa (2013); Gleevec (2015)

Novartis is bracing for some ugly patent exclusivity losses, with ­blockbuster Femara having gone off patent and $2.3-billion Diovan, the company's top seller, facing generic competition in September. Next year, $642-million Zometa goes over the patent cliff, and in 2015, $1.5-billion Gleevec loses exclusivity. But the Swiss giant has cobbled together an Alpine portfolio from steadily-performing smaller brands while diversifying its business into generics (Sandoz), vaccines and diagnostics and, most recently, vision care with its acquisition of Alcon in 2010. The company boasts a muscular R&D operation, as evidenced by MS drug Gilenya, a likely blockbuster approved in 2010, and Arcapta Neohaler for COPD, approved in July, along with a robust late-stage pipeline. However, Novartis has been plagued by manufacturing issues at plants in Quebec and Nebraska. Other potential pitfalls include safety concerns about Gilenya that could hamper that key product's potential, and FDA delays on approvals of the Menveo vaccine and Seebri Breez­haler (NVA237).

Back to first page

Page 4 of 21
Share this article:

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"